Insurers want more time to decide on 2018 ACA exchange participation

With Congress and the next president promising repeal of the Affordable Care Act (ACA), the nation’s largest health insurance lobby wants a delay for insurers to submit plans to offer coverage on the law’s exchanges for 2018.

The New York Times reports America’s Health Insurance Plans (AHIP) has been speaking with congressional leaders over the past several weeks about their priorities in a repeal-and-delay scenario. Among the demands is pushing back the state-by-state deadlines for insurers to file exchange plans for regulatory approval until the summer of 2017.

What AHIP won’t do is fight repeal efforts from Republicans and President-elect Donald Trump. It is endorsing the idea of a long delay in the repeal’s effects to allow time to craft and pass a replacement plan.

“We would love to see a three-year time frame, as long as possible,” said AHIP CEO Marilyn Tavenner.

To find out what insurers want in terms of extending cost-sharing and subsidies over that transition period, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup